Connecticut is currently home to 1231 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Digoxin In Treatment of Alcohol Associated Hepatitis
NCT05014087
Recruiting
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin administration and dose adjustment. The study intervention will be intravenous digoxin (renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized allocation of patients with severe acute alcohol associated hepatitis.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
03/13/2025
Locations: Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut
Conditions: Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Register for Updates
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
NCT06635954
Recruiting
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Eastern Connecticut Hematology and Oncology, Norwich, Connecticut
Conditions: Cancer, Immunotherapy, PD-1, PD-L1, Immune Checkpoint Therapy
Register for Updates
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097
Recruiting
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Datopotamab Deruxtecan (i.v. infusion) compared with osimertinib (tablet) monotherapy as a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study details include: 1. The study duration will be event-driven, with an estimated duration of approximately 9 years. 2. Participants may receive study treatment until disease progression, unac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Research Site, New Haven, Connecticut
Conditions: Non-small Cell Lung Cancer
Register for Updates
Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1
NCT06069791
Recruiting
The acute and subacute sensations that occur on the scalp with injection of different concentrations of bupivacaine for grater occipital nerve blockade will be compared. Each Veteran participant will be randomized to receive three different concentrations, which will be injected one week apart each.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Post-Traumatic Headache
Register for Updates
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019
Recruiting
To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm registry will further assess the safety and effectiveness of the Shockwave Reducer in selected subjects wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Refractory Angina
Register for Updates
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
NCT05002816
Recruiting
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Multiple Myeloma
Register for Updates
Catheter-Related Early Thromboprophylaxis with Enoxaparin Studies
NCT04924322
Recruiting
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/12/2025
Locations: Yale-New Haven Children's Hospital, New Haven, Connecticut
Conditions: Deep Venous Thrombosis
Register for Updates
Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
NCT04738825
Recruiting
The proposed study will be a 24-week intervention with a 12-month follow-up period to evaluate the impact of contingency management with stepped care to pre-exposure prophylaxis (PrEP) adherence and support services (CoMPASS) to promote HIV prevention among individuals with opioid use disorder who have injected drugs in their lifetime. In parallel, the investigators will conduct an implementation focused process evaluation to inform real-world implementation of CoMPASS. .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Recovery Network of Programs, Inc, Bridgeport, Connecticut
Conditions: Opioid-use Disorder, HIV Prevention Program
Register for Updates
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156
Recruiting
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Smilow Cancer Center at YNHH, New Haven, Connecticut
Conditions: Myelofibrosis
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors
NCT06384352
Recruiting
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined. Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211. Part 3 is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven, North Haven, Connecticut
Conditions: Advanced Solid Tumors
Register for Updates
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
NCT06315491
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Register for Updates